Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis

Neurobiol Aging. 2011 Sep;32(9):1531-41. doi: 10.1016/j.neurobiolaging.2009.10.012. Epub 2009 Nov 14.

Abstract

Alzheimer's disease (AD) can present with non-amnestic clinical syndromes. We investigated whether there is an imaging signature of AD pathology in these atypical subjects. We identified 14 subjects that had pathological AD, a non-amnestic presentation (i.e. atypical AD), and MRI. These subjects were matched to 14 with clinical and pathological AD (i.e. typical AD), 14 with the same non-amnestic presentations with frontotemporal lobar degeneration (FTLD) pathology, and 20 controls. Voxel-based morphometry and region-of-interest (ROI) analysis were used to assess patterns of grey matter loss. Loss was observed in the temporoparietal cortex in both typical and atypical AD, and showed significantly greater loss than FTLD. However, the medial temporal lobes were more severely affected in typical AD and FTLD compared to atypical AD. A ratio of hippocampal and temporoparietal volumes provided excellent discrimination of atypical AD from FTLD subjects. Temporoparietal atrophy may therefore provide a useful marker of the presence of AD pathology even in subjects with atypical clinical presentations, especially in the context of relative sparing of the hippocampus.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / pathology*
  • Atrophy
  • Biomarkers
  • Diagnosis, Differential
  • Disease Progression
  • Female
  • Frontotemporal Dementia / diagnosis
  • Frontotemporal Dementia / pathology
  • Hippocampus / pathology*
  • Humans
  • Image Processing, Computer-Assisted / methods
  • Male
  • Middle Aged
  • Parietal Lobe / pathology*
  • Temporal Lobe / pathology*

Substances

  • Biomarkers